Clinical Laboratory, Dongyang People's Hospital, Dongyang, Zhejiang, China.
PLoS One. 2019 Sep 5;14(9):e0221374. doi: 10.1371/journal.pone.0221374. eCollection 2019.
Studies have shown that D-dimer levels are significantly correlated with the differential diagnosis and clinicopathological features of breast cancer. However, the results are currently limited and controversial. Therefore, we performed this meta-analysis to evaluate the relationship between D-dimer levels and breast cancer.
The PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure, Chinese Biomedical Literature, and Wanfang databases were searched to find studies that assessed the association of D-dimer with clinicopathological features of breast cancer and its usefulness in aiding with differential diagnosis. The standardized mean difference (SMD) was applied as the correlation measure.
A total of 1244 patients with breast cancer from 15 eligible studies were included in the meta-analysis. D-dimer levels were higher in the breast cancer group than in the benign (SMD = 1.02; 95% confidence interval [CI] = 0.53-1.52) and healthy (SMD = 1.27; 95% CI = 0.85-1.68) control groups. In addition, elevated D-dimer levels were associated with progesterone receptor-negative tumors (SMD = -0.25; 95% CI = -0.44--0.05). Similarly, there was a significant correlation between D-dimer levels and tumor node metastasis staging (n = 11, SMD = 0.82; 95% CI = 0.57-1.06) and lymph node involvement (n = 8, SMD = 0.79; 95% CI = 0.50-1.09). In contrast, other clinicopathological factors, including estrogen receptor expression and human epidermal growth factor receptor 2 expression, were not associated with D-dimer levels.
The results of this meta-analysis indicate that plasma D-dimer levels can be used as an important reference for the early identification and staging of breast cancer.
研究表明，D-二聚体水平与乳腺癌的鉴别诊断和临床病理特征显著相关。然而，目前的结果有限且存在争议。因此，我们进行了这项荟萃分析，以评估 D-二聚体水平与乳腺癌之间的关系。
我们检索了 PubMed、Embase、Cochrane 图书馆、中国知网、中国生物医学文献数据库和万方数据库，以查找评估 D-二聚体与乳腺癌临床病理特征相关性及其在辅助鉴别诊断中的作用的研究。采用标准化均数差（SMD）作为相关度量。
共有 15 项符合条件的研究纳入了 1244 例乳腺癌患者的荟萃分析。乳腺癌组的 D-二聚体水平高于良性组（SMD=1.02；95%置信区间[CI]：0.53-1.52）和健康对照组（SMD=1.27；95%CI：0.85-1.68）。此外，D-二聚体水平升高与孕激素受体阴性肿瘤相关（SMD=-0.25；95%CI：-0.44--0.05）。同样，D-二聚体水平与肿瘤淋巴结转移分期（n=11，SMD=0.82；95%CI：0.57-1.06）和淋巴结受累（n=8，SMD=0.79；95%CI：0.50-1.09）之间存在显著相关性。相比之下，其他临床病理因素，包括雌激素受体表达和人表皮生长因子受体 2 表达，与 D-二聚体水平无关。
这项荟萃分析的结果表明，血浆 D-二聚体水平可作为早期识别和分期乳腺癌的重要参考。
